An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-11-18

Study Completion Date

2026-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunotherapy as Second-line in Patient With Small Cell Lung Cancer

NCT03059667

Small Cell Lung Cancer Small Cell Lung Cancer Limited Stage Small Cell Lung Cancer Extensive Stage

COMPLETED PHASE2

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

NCT06926673

Neoplasms

COMPLETED PHASE2

A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer

NCT01023347

Non Small Cell Lung Cancer

COMPLETED PHASE2

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

NCT04691817

Lung Cancer, Nonsmall Cell

RECRUITING PHASE1/PHASE2

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

NCT02963090

Small Cell Lung Cancer

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

1\. To evaluate the safety and tolerability of SMS001 in Non-Small Cell Lung Cancer (NSCLC) patients undergoing cancer surgery.

SECONDARY OBJECTIVES:

1. To evaluate tumor recurrence at 12-month follow-up in NSCLC lung cancer patients treated at a predefined dose.
2. To evaluate disease free survival (DFS) for patients treated with SMS001 at the end of study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose Escalation and Confirmation

All participants will receive a one-time administration of SMS001 undergoing their scheduled lung cancer surgery. Participants are given SMS001 and are watched very closely for side effects. If the side effects are manageable, then more participants are asked to join the study and are given a higher dose of SMS001, until a pre-defined suitable dose is reached.

Group Type EXPERIMENTAL

SMS001

Intervention Type DRUG

One time administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SMS001

One time administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paclitaxel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histopathological confirmed NSCLC
2. Stage Ib, IIa, IIb or IIIa (N2) for both dose escalation and dose confirmation (NOTE: Staging will be according to the AJCC 8th edition)
3. Age ≥18 years and suitable for lung cancer surgery
4. No prior chemotherapy and/or thoracic radiation therapy
5. Normal liver, and renal function at study entry
6. Laboratory requirements:

1. WBC \> 2500/mm3
2. Neutrophil \>1500/mm3
3. Hemoglobin \>10 g/dL
4. Platelet \>100,000/ mm3
5. AST and ALT \< 2.5 x ULN
6. Total bilirubin \< 1.5 x ULN
7. Creatinine \< 2 mg/dL (equivalent to 176.8 μmol/L)
8. Normal PT/INR and PTT
9. eGFR \>60mL/min/1.73m²
7. QT interval corrected for heart rate using Frederica's formula (QTcF): males \< 450msec and females \< 470msec
8. Operating surgeon deems patient is candidate for complete surgical resection of lung cancer and lymphadenectomy or lymph node sampling (Wedge resection, segmentectomy or lobectomy are acceptable)
9. Stated willingness to comply with all study procedures and availability for the duration of the study
10. Ability to understand and sign informed consent
11. Women of childbearing potential (WOCBP) must use highly effective methods of contraception for at least 6 months after wafer insertion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 y postmenopausal) or be surgically sterile. Men must use highly effective methods of contraception for at least 3 months after wafer insertion. Examples of highly effective contraception include: parenteral contraceptives, oral contraceptives, patch contraceptives, implantable hormonal contraceptives, intrauterine device or system, surgical sterilization (hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy), tubal ligation/occlusion, vasectomized partner, or sexual abstinence, if this is the subject's current practice. Periodic abstinence, i.e., calendar, symptothermal, or post-ovulation methods are not an acceptable form of contraception for this study.

Exclusion Criteria

If a subject meets any of the following criteria, he/she must be excluded from the study.

1. Evidence of locally advanced T3 or T4 NSCLC or distant metastatic disease.
2. Patients requiring pneumonectomy or sleeve resection.
3. Known sensitivity to any of the study agent components.
4. Patients with a previous malignancy within the last 5 years except non-melanoma skin cancer.
5. Patients receiving induction (neo-adjuvant) chemotherapy and/or radiation prior to surgery.
6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. dysfunction of major organ (e.g., liver, kidney etc.), symptomatic congestive heart failure. unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
7. Pregnant or nursing female subjects.
8. Unwilling or unable to follow protocol requirements.
9. Any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No